Jill Makin

Jill has worked for Touchlight since 2012, driving the transformation of the dbDNA technology from discovery into a robust and scalable DNA manufacturing platform, into GMP production and now supplying customers from two European sites.

In her current role, she oversees a group whose focus is to continually improve the manufacturing offering (transferring these improvements into the CDMO) and expand the utility of dbDNA, building on the strong IP portfolio. Jill also provides development oversight to products arising from the product discovery team and heading towards the clinic.

Prior to Touchlight, Jill worked in senior R&D roles, and as a consultant, in the biotech/vaccine industry, including positions at Emergent BioSolutions, Celltech-Medeva, and a number of start-ups.

Jill holds a Ph.D. in influenza research.